Highly Active Antiretroviral Therapy for treatment of HIV/AIDS patients: Current status and future prospects and the Indian scenario

HIV and AIDS Review

Volumn 11, Issue 1, 2012, Pages 5-14

  Kumari, Garima ^a   Singh, Ramendra K ^a  

^a UNIVERSITY OF ALLAHABAD   (India)

Author keywords

Drug targets; FDCs; HAART; HIV; Indian scenario; Viral reservoirs

Indexed keywords

1 ACETYL N [3 [4 (4 CARBAMOYLBENZYL) 1 PIPERIDINYL]PROPYL] N (3 CHLORO 4 METHYLPHENYL) 4 PIPERIDINECARBOXAMIDE; 2',3' DIDEHYDRO 2',3' DIDEOXY 2' FLUORO 5' O PHOSPHONOMETHYLADENOSINE; 8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMDOXOVIR; APLAVIROC; APRICITABINE; CALANOLIDE A; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; ELVUCITABINE; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; FOSDEVIRINE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INTEGRASE INHIBITOR; LAMIVUDINE PLUS ZIDOVUDINE; MARAVIROC; MICROBICIDE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PF 232798; PROTEINASE INHIBITOR; RALTEGRAVIR; RDEA 806; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL ACTIVITY; BLOOD; BLOOD BRAIN BARRIER; BREAST MILK; CD4+ T LYMPHOCYTE; DISEASE CARRIER; DISEASE SURVEILLANCE; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG RESISTANCE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOXICITY; EPIDEMIC; FIXED DOSE REGIMEN; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; INFECTION CONTROL; INFECTION PREVENTION; LIFE CYCLE; LIPODYSTROPHY; MULTIDRUG RESISTANCE; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PREMATURE EJACULATION; PROVIRUS; REVERSE TRANSCRIPTION; REVIEW; RISK REDUCTION; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SPERM; STEM CELL TRANSPLANTATION; VACCINATION; VAGINA DISCHARGE; VERTICAL TRANSMISSION; VIREMIA; VIRION; VIRUS ATTACHMENT; VIRUS CAPSID; VIRUS ENTRY; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS STRAIN;

EID: 84862796955     PISSN: 17301270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hivar.2012.02.003     Document Type: Review

References (88)

1. F. Barré-Sinoussi, J.C. Chermann, F. Rey, M.T. Nugeyre, S. Chamaret, J. Gruest, C. Dauguet, C. Axler-Blin, F. Vézinet-Brun, C. Rouzioux, W. Rozenbaum, and L. Montagnier Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS) Science 220 1983 868 871
2. R.C. Gallo, P.S. Sarin, E.P. Gelmann, M. Robert-Guroff, E. Richardson, V.S. Kalyanaraman, D. Mann, G.D. Sidhu, R.E. Stahl, S. Zolla-Pazner, J. Leibowitch, and M. Popovic Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS) Science 220 1983 865 867 (Pubitemid 13080156)
3. J.T. King Jr., A.C. Justice, M.S. Roberts, C.C. Chang, and J.S. Fusco Collaboration in HIV outcomes research - U.S. Program Team. Long-term HIV-AIDS survival estimation in the highly active antiretroviral therapy era Med. Decis. Making 23 2003 9 20 (Pubitemid 36133356)
4. C.M. Kitchen, S.G. Kitchen, J.A. Dubin, and M.S. Gottieb Initial virological and immunologic response to highly active antiretroviral therapy predicts long-term clinical outcome Clin. Infect. Dis. 33 2001 466 472 (Pubitemid 32709577)
5. W.M. Valenti HAART is a cost-effective and improves outcomes AIDS Reader 11 2001 260 262
6. A. Carr Toxicity of antiretroviral therapy and implications for drug development Nat. Rev. Drug Discov. 2 2003 624 634 (Pubitemid 37361766)
7. J. Martinez-Picado, M.P. De Pasquale, N. Kartsonis, G.J. Hanna, J. Wong, D. Finzi, E. Rosenberg, H.F. Gunthard, L. Sutton, A. Savara, C.J. Petropoulos, N. Hellmann, B.D. Walker, D.D. Richman, R. Siliciano, and R.T. D'Aquila Antiretroviral resistance during successful therapy of HIV type 1 infection Proc. Natl. Acad. Sci. U.S.A.U. S. A. 97 2000 10948 10953
8. S.J. Little, S. Holte, J.P. Routy, E.S. Daar, M. Markowitz, A.C. Collier, R.A. Koup, J.W. Mellors, E. Connick, B. Conway, M. Kilby, L. Wang, J.M. Whitcomb, N.S. Hellmann, and D.D. Richman Antiretroviral-drug resistance among patients recently infected with HIV N. Engl. J. Med. 347 2002 385 394 (Pubitemid 34851830)
9. M. Popovic, M.G. Sarngadharan, E. Read, and R.C. Gallo Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS Science 224 1984 497 500 (Pubitemid 14134740)
10. S. Broder The development of antiretroviral therapy and its impact on the global HIV-1/AIDS pandemic Antiviral Res. 85 2010 1 18
11. H. Mitsuya, K.J. Weinhold, P.A. Furman, St. M.H. Clair, S.N. Lehrman, R.C. Gallo, D. Bolognesi, D.W. Barry, and S. Broder 3′-Azido-3′- deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy- associated virus in vitro Proc. Natl. Acad. Sci. U.S.A.U. S. A. 82 1985 7096 7100 (Pubitemid 16209699)
12. C.C. Carpenter, M.A. Fischl, S.M. Hammer, M.S. Hirsch, D.M. Jacobsen, D.A. Katzenstein, J.S. Montaner, D.D. Richman, M.S. Saag, R.T. Schooley, M.A. Thompson, S. Vella, P.G. Yeni, and P.A. Volberding Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel JAMA 277 1997 1962 1969 (Pubitemid 27272775)
13. J. Balzarini, G.J. Kang, M. Dalal, P. Herdewijn, E. De Clercq, S. Broder, and D.G. Johns The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2′,3′-didehydro-2′,3′-dideoxyribonucleosides: a comparison with their parental 2′,3′-dideoxyribonucleosides Mol. Pharmacol. 32 1987 162 167 (Pubitemid 17112329)
14. S.M. Daluge, S.S. Good, M.B. Faletto, W.H. Miller, St.M.H. Clair, L.R. Boone, M. Tisdale, N.R. Parry, J.E. Reardon, R.E. Dornsife, D.R. Averett, and T.A. Krenitsky 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity Antimicrob. Agents Chemother. 41 1997 1082 1093 (Pubitemid 27194190)
15. G. Gosselin, R.F. Schinazi, J.P. Sommadossi, C. Mathe, M.C. Bergogne, A.M. Aubertin, A. Kirn, and J.L. Imbach Antihuman immunodeficiency virus activities of the beta-L enantiomer of 2′,3′-dideoxycytidine and its 5-fluoro derivative in vitro Antimicrob. Agents Chemother. 38 1994 1292 1297 (Pubitemid 24170709)
16. R.F. Schinazi, A. McMillan, D. Cannon, R. Mathis, R.M. Lloyd, A. Peck, J.P. Sommadossi, St M.J. Clair, J. Wilson, P.A. Furman, G. Painter, W.-B. Choi, and D.C. Liotta Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1, 3-oxathiolan-5-yl]cytosine Antimicrob. Agents Chemother. 36 1992 2423 2431
17. J. Balzarini Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives Pharm. World Soc. 16 1994 113 126 (Pubitemid 24142453)
18. Z. Hao, D.A. Cooney, D. Farquhar, C.F. Perno, K. Zhang, R. Masood, Y. Wilson, N.R. Hartman, J. Balzarini, and D.G. Johns DNA chain termination activity and selective inhibition of human immunodeficiency virus reverse transcriptase by 2′,3′-dideoxyuridine-5′-triphosphate Mol. Pharmacol. 37 1990 157 163 (Pubitemid 20082978)
19. J.M. De Muys, H. Gourdeau, N. Nguyen-Ba, D.L. Taylor, P.S. Ahmed, T. Mansour, C. Locas, N. Richard, M.A. Wainberg, and R.F. Rando Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2′-deoxy-3′-oxa-4′-thiocytidine Antimicrob. Agents Chemother. 43 1999 1835 1844 (Pubitemid 29395173)
20. R.F. Schinazi, A. McMillan, D. Cannon, R. Mathis, R.M. Lloyd, A. Peck, J.P. Sommadossi, St.M. Clair, J. Wilson, P.A. Furman, G. Painter, W.-B. Choi, and D.C. Liotta Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1, 3-oxathiolan-5-yl]cytosine Antimicrob. Agents Chemother. 36 1992 2423 2431
21. H.O. Kim, R.F. Schinazi, K. Shanmuganathan, L.S. Jeong, J.W. Beach, S. Nampalli, D.L. Cannon, and C.K. Chu L-β-(2S, 4S)- and L-α-(2S,4R)- Dioxolanyl nucleosides as potential anti-HIV agents: asymmetric synthesis and structure-activity relationships J. Med. Chem. 36 1993 519 528 (Pubitemid 23097416)
22. T.S. Lin, M.Z. Luo, M.C. Liu, S.B. Pai, G.E. Dutschman, and Y.C. Cheng Antiviral activity of β-L(-)-2′,3′-dideoxy-5-fluoro-cytidine (L(-)ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro Biochem. Pharmacol. 47 1994 171 174
23. R.C. Bethell, Y.S. Lie, and N.T. Parkin In vitro activity of SPD754, a new deoxycitidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs, Antiviral Chem. Chemother. 16 2005 295 302 (Pubitemid 41405996)
24. Z. Gu, B. Allard, J.M. de Muys, J. Lippens, R.F. Rando, N. Nguyen-Ba, C. Ren, P. McKenna, D.L. Taylor, and R.C. Bethell In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection Antimicrob. Agents Chemother. 50 2006 625 631 (Pubitemid 43190975)
25. P. Cahn, I. Cassetti, R. Wood, P. Phanuphak, L. Shiveley, R.C. Bethell, and J. Sawyer Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naïve, HIV-infected patients AIDS 20 2006 1261 1268 (Pubitemid 44030374)
26. S. Cox, S. Moore, J. Southby, and A. Alsumbe Safety profile of apricitabine, a novel NRTI, during 24-week dosing in experienced HIV-1 infected patients XVII International AIDS Conference Mexico City, Mexico, August 3-8 2008 abstract no. TUAB0106
27. I. Cassetti, J.V.R. Madruga, J.M.A.H. Suleiman, A. Etzel, L.J. Zhong, A.K. Cheng, and J. Enejosa The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients HIV Clin. Trials 8 2007 164 172 (Pubitemid 47121761)
28. J.E. Gallant, S. Straszewski, A.L. Pozniak, E. DeJesus, J.M.A.H. Suleiman, M.D. Miller, D.F. Coakley, B. Lu, J.J. Toole, and A.K. Cheng Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients. A 3-year randomized trial JAMA 292 2004 191 201 (Pubitemid 38917996)
29. J.R. Arribas, A.L. Pozniak, J.E. Gallant, E. Dejesus, B. Gazzard, R.E. Campo, S.S. Chen, D. McColl, C.B. Holmes, J. Enejosa, J.J. Toole, and A.K. Cheng Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naïve patients: 144-week analysis J. Acquir. Defic. Syndr. 47 2008 74 78 (Pubitemid 351619372)
30. T. Cihlar, A. Ray, D. Boojamra, L. Zhang, H. Hui, D. Grant, K. White, M. Desai, N. Parkin, and R. Mackman GS9148: a novel nucleotide active against HIV-1 variants with drug resistance mutations in reverse transcriptase 13th Conference on Retroviruses and Opportunistic Infections Denver, CO, February 5-8 2006 abstract no. 45
31. E. De Clercq Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present and future Chem. Biodivers. 1 2004 44 64
32. M. Baba, H. Tanaka, E. De Clercq, R. Pauwels, J. Balzarini, D. Schols, H. Nakashima, C.-F. Perno, R.T. Walker, and T. Miyasaka Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative Biochem. Biophys. Res. Commun. 165 1989 1375 1381 (Pubitemid 20029862)
33. V.J. Merluzzi, K.D. Hargrave, M. Labadia, K. Grozinger, M. Skoog, J.C. Wu, C.K. Shih, K. Eckner, S. Hattox, J. Adams, A.S. Rosenthal, R. Faanes, R.J. Eckner, R.A. Koup, and J.L. Sullvian Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor Science 250 1990 1411 1413 (Pubitemid 120031860)
34. R. Pauwels New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections Curr. Opin. Pharmacol. 4 2004 437 446 (Pubitemid 40533003)
35. R. Pauwels, K. Andries, J. Desmyter, D. Schols, M.J. Kukla, H.J. Breslin, A. Raeymaeckers, J. Van Gelder, R. Woestenborghs, J. Heykants, K. Schellekens, M.A.C. Janssen, E. De Clercq, and P.A. Janssen Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives Nature 343 1990 470 474 (Pubitemid 120028562)
36. K. Andries, M.-p. de Bethune, M.J. Kukla, H. Azijn, P.J. Lewi, P.A.J. Janssen, and R. Pauwels R165335-TMC125, a novel nonnucleoside reverse transcriptase inhibitor (NNRTI) with nanomolar activity against NNRTI resistant HIV strains 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada, September 17-20 2000 abstract no. 1840
37. T.J. Dueweke, S.M. Poppe, D.L. Romero, S.M. Swaney, A.G. So, K.M. Downer, I.W. Althaus, F. Reusser, M. Busso, L. Resnick, D. Mayers, J. Lane, P.A. Aristoff, R.C. Thomas, and W.G. Tarpley U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication Antimicrob. Agents Chemother. 37 1993 1127 1131 (Pubitemid 23141331)
38. R.A. Domaoal, and L.M. Demeter Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors Int. J. Biochem. Cell Biol. 36 2004 1735 1751 (Pubitemid 38750243)
39. P.A. Janssen, P.J. Lewi, E. Arnold, F. Daeyaert, M. De Jonge, J. Heeres, L. Koymans, M. Vinkers, J. Guillemont, E. Pasquier, M. Kukla, D. Ludovici, K. Andries, and M.P. De Bethune In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[4-[[4-[(1E)-2, 6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine) J. Med. Chem. 48 2005 1901 1909 (Pubitemid 40396320)
40. M.T. Flavin, J.D. Rizzo, A. Khilevich, A. Kucherenko, A.K. Shwinkman, V. Vilaychack, L. Lin, W. Chen, E.M. Greenwood, T. Pengsuparp, J.M. Pezzuto, S.H. Hughes, T.M. Flavin, W.A. Boulanger, R.L. Shone, and Z.Q. Xu Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+)-calanolide A and its enantiomers J. Med. Chem. 39 1996 1303 1313 (Pubitemid 26089845)
41. D.D. Richman, C.B. Dousson, R. Storer, A. Moussa, J. Randall, E. Bridges, M. Liuzzi, J. Jakubik, M. Seifer, and D. Standring IDX12899 and IDX12989, novel NNRTI with potent anti-HIV activity, enhanced barrier to resistance and favorable pharmacokinetic profile 14th Conference on Retroviruses and Opportunistic Infections Los Angeles, February 25-28 2007 CA abstract 489
42. H. Zhang, B. Oberg, D. Bottiger, D. Phillips, J.F. Romeo, M. Thom, and L. Vrang MIV-150 in a vaginal microbicide with superior anti-HIV activities Presented at the XV International AIDS Conference Bangkok, Thailand, July 12-16 2004 abstract no. TuPeB4667
43. J.-L. Girardet, Y.-H. Koh, M. De La Rosa, E. Gunic, Z. Zhang, R. Hamatake, and L. Yeh The discovery of RDEA806, a potent new HIV NNRTI in phase 1 clinical trials 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL, September 17-20 2007 abstract no. 3285
44. P. Bonneau, P. Robinson, J. Duan, L. Doyon, B. Simoneau, C. Yoakim, M. Garneau, M. Bos, M. Cordingley, B. Brenner, B. Spira, M. Wainberg, F. Huang, K. Drda, C. Ballow, and D. Mayers Antiviral characterization and human experience with BILR 355 BS, a novel next-generation non-nucleoside reverse transcriptase inhibitor with a broad anti HIV-1 profile 12th Conference on Retroviruses and Opportunistic Infections Boston, MA, February 22-25 2005 abstract no. 558
45. Z.K. Sweeney, and K. Klumpp Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data Curr. Opin. Drug Discov. Devel. 11 2008 458 470 (Pubitemid 351950841)
46. Y. Kashman, K.R. Gustafson, R.W. Fuller, J.H. Cardellina, J.B. McMohan, M.J. Currens, R.W. Buckheit, S.H. Hughes, G.M. Cragg, and M.R. Boyd HIV inhibitory natural products. Part 7. The calanolides, a novel HIV-inhibitory class of coumarin derivative from the tropical rain forest tree, Calophyllum lanigerum J. Med. Chem. 35 1992 2735 2743
47. E. De Clercq New approaches towards anti-HIV chemotherapy J. Med. Chem. 48 2005 1297 1313 (Pubitemid 40364540)
48. J.M. Molina, and A. Hill Darunavir (TMC114): a new HIV-1 protease inhibitor Expert Opin. Pharmacother. 8 2007 1951 1964 (Pubitemid 47316150)
49. Z. Temesgen, F. Cainelli, and S. Vento Tipranavir Drugs Today 41 2005 711 720 (Pubitemid 43074781)
50. K. Bragman Sanquinavir Adv. Exp. Med. Biol. 394 1996 305 317
51. A.P. Lea, and D. Faulds Ritonavir Drugs 52 1996 541 546
52. G.L. Plosker, and S. Noble Indinavir: a review of its use in the management of HIV infection Drugs 58 1999 1165 1203 (Pubitemid 30055050)
53. P. Tebas, and W.G. Powderly Nelfinvir mesylate Expert Opin. Pharmacother. 1 2000 1429 1440
54. J.C. Adkins, and D. Faulds Amprenavir Drugs 55 1998 837 842
55. E.M. Mangum, and K.K. Graham Lopinavir-ritonavir: a new protease inhibitor Pharmacotherapy 21 2001 1352 1363
56. S. Becker, and L. Thornton Fosamprenavir: advancing HIV protease inhibitor treatment options Expert Opin. Pharmacother. 5 2004 1995 2005 (Pubitemid 39236600)
57. J.J. Orrick, and C.R. Steinhart Atazanavir Ann. Pharmacother. 38 2004 1664 1674 (Pubitemid 39297767)
58. T. Matthews, M. Salgo, M. Greenberg, J. Chung, R. DeMasi, and D. Bolognesi Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes Nat. Rev. Drug Discov. 3 2004 215 225 (Pubitemid 38379988)
59. C. Wild, T. Greenwell, and T. Matthews A synthetic peptide from HIV-1 gp41is a potent inhibitor of virus-mediated cell-cell fusion AIDS Res. Hum. Retroviruses 9 1993 1051 1053
60. J.T. Ernst, O. Kutzki, A.K. Debnath, S. Jiang, H. Lu, and A.D. Hamilton Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion Angew. Chem. Int. Ed. 41 2002 278 281 (Pubitemid 34118069)
61. E.A. Berger, R.W. Doms, E.M. Fenyo, B.T. Korber, D.R. Littman, J.P. Moore, Q.J. Sattentau, H. Schuitemaker, J. Sodroski, and R.A. Weiss A new classification for HIV-1 Nature 392 1998 240
62. P. Dorr, M. Westby, S. Dobbs, P. Griffin, B. Irvine, M. Macartney, J. Mori, G. Rickett, C. Smith-Burchnell, C. Napier, R. Webster, D. Armour, D. Price, B. Stammen, A. Wood, and M. Perros Maraviroc (UK-427, 857), a potent, orally bioavailable and selective small-molecule inhibitor of chemokines receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity Antimicrob. Agents Chemother. 49 2005 4721 4732 (Pubitemid 41552605)
63. J.M. Strizki, C. Tremblay, S. Xu, L. Wojcik, N. Wanger, W. Gonsiorek, R.W. Hipkin, C.C. Chou, C. Pugliese-Sivo, Y. Xiao, J.R. Tagat, K. Cox, T. Priestley, S. Sorota, W. Huang, M. Hirsch, G.R. Reyes, and B.M. Baroudy Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1 Antimicrob. Agents Chemother. 49 2005 4911 4919 (Pubitemid 41782160)
64. K. Takashima, H. Miyake, N. Kanzaki, Y. Tagawa, X. Wang, Y. Sugihara, Y. Iizawz, and M. Baba Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist Antimicrob. Agents Chemother. 49 2005 3474 3482 (Pubitemid 41060598)
65. P. Dorr, M. Westby, L. McFadyen, J. Mori, J. Davis, F. Perruccio, R. Jones, P. Stuppe, and D. Middleton PF-232798, a second generation Pfizer oral CCR5 antagonist 15th Conference on Retroviruses and Opportunistic Infections Boston, MA, February 3-6 2008 abstract no. 737
66. V. Idemyor Human immunodeficiency virus (HIV) entry inhibitors (CCR5 specific blockers) in development: are they the next novel therapies? HIV Clin. Trials 6 2005 272 277 (Pubitemid 43025158)
67. Y. Pommier, A.A. Johnson, and C. Marchand Integrase inhibitors to treat HIV/AIDS Nat. Rev. Drug Discov. 4 2005 236 248 (Pubitemid 40372557)
68. R. Craigie HIV integrase, a brief overview from chemistry to therapeutics J. Biol. Chem. 276 2001 23213 23216
69. V. Summa, A. Petrocchi, F. Bonelli, B. Crescenzi, M. Donghi, M. Ferrara, F. Fiore, C. Gardelli, O.G. Paz, D.J. Hazuda, P. Jones, O. Kinzel, R. Laufer, E. Monteagudo, E. Muraglia, E. Nizi, F. Orvieto, P. Pace, G. Pescatore, R. Scarpelli, K. Stillmock, M.V. Witmer, and M. Rowley Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection J. Med. Chem. 51 2008 5843 5855
70. A.S. Fauci The AIDS epidemic. Considerations for the 21st century N. Engl. J. Med. 341 1999 1046 1050 (Pubitemid 29451801)
71. S.H. Michaels, R. Clark, and P. Kissinger Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection N. Engl. J. Med. 339 1998 405 406 (Pubitemid 28363808)
72. P.P. Sendi, H.C. Bucher, B.A. Craig, and M. Pfluger Estimating AIDS-free survival in a severely immunosuppressed asymptomatic HIV-infected population in the era of antiretroviral triple combination therapy. Swiss HIV Cohort Study J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20 1999 376 381 (Pubitemid 29143032)
73. L. Menendez-Arias Molecular basis of Human Immunodeficiency Virus drug resistance: an update Antiviral Res. 85 2010 210 231
74. L. Osterberg, and T. Blaschke Adherence to medication N. Engl. J. Med. 353 2005 487 497 (Pubitemid 41127293)
75. M.A. Chesney, M. Morin, and L. Sherr Adherence to HIV combination therapy Soc. Sci. Med. 50 2000 1599 1605 (Pubitemid 30129133)
76. S. Mehta, R.D. Moore, and N.M. Graham Potential factors affecting adherence with HIV therapy AIDS 11 1997 1665 1670 (Pubitemid 27470267)
77. N.H. Miller Compliance with treatment regimens in chronic asymptomatic diseases Am. J. Med. 102 1997 43 49 (Pubitemid 27147947)
78. J. Falutz, S. Allas, K. Blot, D. Potvin, D. Kotler, M. Somero, D. Berger, S. Brown, G. Richmond, J. Fessel, R. Turner, and S. Grinspoon Metabolic effects of a growth hormone-releasing factor in patients with HIV N. Engl. J. Med. 357 2007 2359 2370 (Pubitemid 350223390)
79. A. Calmy, B. Hirschel, D.A. Cooper, and A. Carr A new era of antiretroviral drug toxicity Antivir. Ther. 14 2009 165 179
80. J. Fox, and S. Fidler Sexual transmission of HIV Antivirol Res. 85 2010 276 285
81. R.H. Haubrich, S.A. Riddler, A.G. DiRienzo, L. Komarow, W.G. Powderly, K. Klingman, K.W. Garren, D.L. Butcher, J.F. Rooney, D.W. Haas, J.W. Mellors, and D.V. Havlir Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment AIDS 23 2009 1109 1118
82. S.A Riddler, R. Haubrich, A.G. DiRienzo, L. Peeples, W.G. Powderly, K.L. Klingman, K.W. Garren, T. George, J.F. Rooney, B. Brizz, U.G. Lalloo, R.L. Murphy, S. Swindells, D. Havlir, and J.W. Mellors Class-sparing regimens for initial treatment of HIV-1 infection N. Engl. J. Med. 358 2008 2095 2106 (Pubitemid 351679596)
83. J.E. McKinnon, J.W. Mellors, and S. Swindells Simplification strategies to reduce antiretroviral drug exposure: progress and prospects Antivir. Ther. 14 2009 1 12
84. A.R. Zolopa The evolution of HIV treatment guidelines: current state-of-the art of ART Antiviral Res. 85 2010 241 244
85. W.C. Greene, Z. Debyser, Y. Ikeda, E.O. Freed, E. Stephens, W. Yonemoto, R.W. Buckheit, J.A. Este, and T. Cihlar Novel targets for HIV therapy Antiviral Res. 80 2008 251 265
86. Y. Levy, C. Lacabaratz, L. Weiss, J.P. Viard, C. Goujard, J.D. Lelievre, F. Boue, J.M. Molina, C. Rouzioux, V. Avettand-Fenoel, T. Croughs, S. Beq, R. Thiebaut, G. Chene, M. Morre, and J.F. Delfraissy Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment J. Clin. Invest. 119 2009 997 1007
87. R.W. Buckheit, K.M. Watson, K. Moorrow, and A.S. Ham Development of topical microbicides to prevent the sexual transmission of HIV Antiviral Res. 85 2010 142 158
88. C.J. Elias, and L.L. Heise Challenges for the development of female-controlled vaginal microbicides AIDS 8 1994 1 10